Veda Giri, MD
Genetic testing has created an impact in breast, ovarian, and prostate cancers, in terms of screening and therapeutic decisions for patients, explains Veda Giri, MD. The importance of genetics cannot only determine molecular mutations that can be targeted, but also who might be at risk for prostate cancer.
State of the Science Summit™ on Prostate Cancer, Giri, an associate professor at Thomas Jefferson University Hospital, discussed the developing role of genetic testing for the screening and management of patients with prostate cancer.
OncLive: Please provide an overview of your presentation on genetic testing for patients with prostate cancer.
It is an exciting time for genetic testing and evaluation for patients with prostate cancer. The role of genetic testing for the management of screening and treatment for men is rising. In my talk, I discussed what the current management recommendations are based on genetic test results—whether it is screening, active surveillance, or emerging clinical trials for patients with metastatic prostate cancer.
... to read the full story